openPR Logo
Press release

Anthrax Market Competitive Landscape Analysis with Forecast by 2025

03-11-2018 06:16 AM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Anthrax Market Competitive Landscape Analysis with Forecast

Anthrax is a lethal disease affecting humans as well as animals such as goat, sheep, horses, and cattle. The causative agent is a gram positive, rod shaped bacterium Bacillus anthracis. Anthrax can spread through three main routes which include aerial route, digestive route and contact through skin. Common symptoms in human beings for respiratory infection include pneumonia and severe respiratory collapse. Gastrointestinal infection is associated with symptoms such as vomiting, severe diarrhea, loss of appetite and digestive tract infections. Anthrax skin infection develops an ulcer with black center called as eschar which is a painless necrotic patch.

Browse Premium Industry Research Report with Analysis:

This form of disease is not fatal if proper treatment is provided. Diagnosis of anthrax infection is done through X-ray and CT scan of lungs, biopsy skin test and blood test for anthrax antigens. Chemiluminescence and Enzyme Linked Immunosorbent Assay (ELISA) based kits are available for diagnosis of anthrax. Anthrax has gained popularity because of its use in bioterrorism. Since long the spores of anthrax have been used for mass infection and in biological warfare. This has led countries across the world to spread awareness about the disease, and also be prepared for any biological attack. In light of past events, as a precaution, the U.S. Postal Service has also installed a biohazard detection system at major distribution centers in order to actively scan for anthrax spores being transported via mail.

Anthrax can be cured if treated in early stages of infection. Cutaneous or skin infection can be treated with common antibiotics such as ciprofloxacin, erythromycin, tetracycline, and penicillin. There is only one vaccine for treating anthrax which is FDA approved. BioThrax manufactured by Emergent BioSolutions, Inc. is provided as pre exposure protection from anthrax infections. Elusys Therapeutics is conducting clinical trials for ETI- 204 for inhalational anthrax. Currently the study (NCT01932437) is under phase I clinical trial. In 2012, U.S. FDA approved drug for treatment of anthrax which is manufactured by GlaxoSmithKline. Raxibacumab, a human IgG1λ monoclonal antibody can be prescribed to adults as well as pediatrics with inhalational anthrax. Various governments are also backing research for anthrax with funding and grants.

Request for Sample Copy of Report:

PharmAthene, Inc. announced in 2010 that the Department of Health and Human Services (HHS) modified the development contract with the company by providing up to USD 78.4 million for development of anthrax vaccine SparVax. SparVax is sub unit vaccine, which comprises of a recombinant protein manufactured in E.coli. Currently the study is in phase II clinical trial. The company is also trying to develop an anti toxin under the brand name Valortim. Valortim is a human monoclonal antibody which targets PA a component of anthrax toxin. By targeting PA, Valortim is believed to protect healthy cells from being damaged by the toxins. Currently the study is under phase I clinical trial.

As majority of the studies are under phase II or phase I trials, outcome of such studies cannot be ascertained. With a keen eye on anthrax infection in humans by government, and existence of few market players have restricted the market growth. Although the treatment for skin infection is cost effective, inhalational and gastrointestinal anthrax treatment is expensive. Moreover the market for anthrax is concentrated to countries under threat for terrorist attacks. The market for diagnosis of anthrax also holds potential in rural areas for diagnosis of cutaneous anthrax, where animal breading is widely practiced.

Request Table of Content of Report:

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact US:

Transparency Market Research,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anthrax Market Competitive Landscape Analysis with Forecast by 2025 here

News-ID: 973163 • Views: 323

More Releases from Transparency Market Research

Utility-Scale Energy Storage Technologies Market Advanced Technology and New Inn …
Global Utility-Scale Energy Storage Technologies Market: Overview The increasing demand for energy is accelerating the deployment of utility-scale energy storage technologies around the world. The benefits offered by these technologies in terms of increasing the efficiency of energy storage are projected to help the market grow in the near future. In addition, the rising demand for reducing the carbon footprint is expected to propel the growth of the global utility-scale energy
Corporate Travel Security Market to Witness an Outstanding Growth during 2019 …
Corporate Travel Security Market: Introduction Transparency Market Research delivers key insights on the corporate travel security market. In terms of revenue, the corporate travel security market is estimated to expand at a CAGR of ~4% during the forecast period, owing to numerous factors regarding which TMR offers thorough insights and forecasts in the corporate travel security market report. In the report, TMR predicts that the corporate travel security market would be
Distribution Automation Market Segmentation Application, Technology and Market A …
Global Distribution Automation Market: Overview Reaching a significant market worth by 2027, the global distribution automation market is set to chart a notable CAGR (Compound Annual Growth Rate) owing to an increase in generation of renewable energy, and a rising demand for energy efficiency. It is worth pointing out here that developing countries such as India are witnessing an increase in distributed energy generation and that is leading a plethora of untapped
Insulated Packaging Market Entry Strategies, Countermeasures of Economic Impact …
Insulated Packaging Market: Introduction Insulation material is defined as a material or combination of different materials having low thermal conductivity to resist the flow of heat. Thermal abuse is the major concern faced during the transportation of temperature sensible products; hence, most of the major industries such as food and beverages, pharmaceutical, healthcare, chemicals, cosmetics, etc., depend heavily on insulated materials for packaging. Products from these industries may be subjected to

All 5 Releases

More Releases for Anthrax

Anthrax Vaccines Market to Witness Robust Expansion by 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global Anthrax Vaccines market. Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against
Anthrax Vaccine Market : A Complete Guide On Global Anthrax Vaccine Market And I …
Global Anthrax Vaccine Market Precision Business Insights (PBI) in its report titled “Global Anthrax Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Anthrax is a bacterial infection caused by Bacillus
Anthrax Market Size & Shares, Strategies and Forecast Worldwide, 2017 - 2025
" Anthrax Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" is the latest addition to MarketResearchReports.Biz industry research reports collection. The objectives of this study are as follows: To define, describe, and forecast the "Anthrax" market by type, application, component, delivery model, end user, and region To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges) To analyze micromarkets with respect to
Anthrax Market Size, Share, Growth, Trends and Forecast 2025
“The Report Anthrax Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -” Anthrax is a lethal disease affecting humans as well as animals such as goat, sheep, horses, and cattle. The causative agent is a gram positive, rod shaped bacterium Bacillus anthracis. Anthrax can spread through three main routes
Anthrax - Pipeline Review, H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H1 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape. Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins
Anthrax Vaccines Market 2017- Merial, Merck, Zoetis
Apex Research, recently published a detailed market research study focused on the "Anthrax Vaccines Market" across the global, regional and country level. The report provides 360° analysis of "Anthrax Vaccines Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Anthrax Vaccines industry, and estimates the future trend of Anthrax Vaccines market on